FM
FMCQF.US Fresenius Medical Care AG & Co. KGaA
- Market cap
- USD 11.6B
- P/E
- 12.9x
- P/B
- 0.81x
- ROE
- 5.2%
- Dividend yield
- 3.89%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FMCQF.US undervalued?
Graham numberFMCQF.US trades 32.0% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fresenius Medical Care AG & Co. KGaA fundamental analysis
No fundamental analysis for Fresenius Medical Care AG & Co. KGaA yet.
Fresenius Medical Care AG & Co. KGaA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis ser…
Full company profileFresenius Medical Care AG & Co. KGaA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fresenius Medical Care AG & Co. KGaA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.0B | 17.8B | 16.5B | 17.5B | 17.9B | 17.6B | 19.4B | 19.5B | 19.3B | 19.6B | 19.2B |
| Gross Profit | 5.50B | 6.00B | 5.16B | 5.40B | 5.54B | 5.08B | 4.89B | 4.93B | 4.76B | 5.03B | 5.02B |
| Operating Income | 2.51B | 2.36B | 3.04B | 710M | 2.30B | 1.90B | 1.51B | 1.37B | 1.39B | 1.84B | 1.85B |
| EBITDA | 3.17B | 3.15B | 3.90B | 3.82B | 4.13B | 3.46B | 3.42B | 3.21B | 3.21B | 3.40B | 3.35B |
| Net Income | 1.18B | 1.28B | 1.98B | 1.20B | 1.16B | 969M | 673M | 499M | 538M | 978M | 661M |
| EPS | 3.87 | 4.18 | 6.47 | 3.96 | 3.96 | 3.31 | 2.30 | 1.70 | 1.83 | 3.36 | 2.51 |
| Balance Sheet | |||||||||||
| Total Assets | 25.6B | 24.0B | 26.2B | 32.9B | 31.7B | 34.4B | 35.8B | 33.9B | 33.6B | 31.0B | 31.4B |
| Total Liabilities | 14.7B | 13.2B | 13.3B | 19.7B | 19.4B | 20.4B | 20.3B | 19.1B | 17.8B | 16.7B | 17.7B |
| Shareholders' Equity | 10.9B | 10.8B | 12.9B | 13.2B | 12.3B | 14.0B | 15.4B | 13.6B | 14.6B | 13.3B | 12.8B |
| Cash & Short-term Investments | 962M | 978M | 2.15B | 1.14B | 1.24B | 1.62B | 1.44B | 1.54B | 1.45B | 1.73B | 1.48B |
| Total Debt | 8.15B | 7.45B | 7.55B | 13.8B | 12.4B | 13.3B | 13.2B | 12.1B | 11.0B | 10.8B | 10.9B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.03B | 2.19B | 2.06B | 2.57B | 4.23B | 2.49B | 2.17B | 2.63B | 2.39B | 2.68B | 2.51B |
| Capital Expenditure | 1.94B | 1.79B | 2.06B | 2.24B | 2.09B | 1.68B | 1.41B | 685M | 699M | 915M | 891M |
| Free Cash Flow | 93.2M | 407M | 2.00M | 329M | 2.15B | 806M | 756M | 1.94B | 1.69B | 1.76B | 1.62B |
| Ratios | |||||||||||
| ROE | 10.8% | 11.8% | 15.4% | 9.1% | 9.4% | 6.9% | 4.4% | 3.7% | 3.7% | 7.3% | 5.2% |
| ROA | 4.6% | 5.3% | 7.6% | 3.6% | 3.7% | 2.8% | 1.9% | 1.5% | 1.6% | 3.2% | 2.1% |
| Net Profit Margin | 6.9% | 7.2% | 12.0% | 6.9% | 6.5% | 5.5% | 3.5% | 2.6% | 2.8% | 5.0% | 3.4% |
| Debt to Equity | 0.75x | 0.69x | 0.58x | 1.04x | 1.00x | 0.95x | 0.86x | 0.88x | 0.75x | 0.81x | 0.85x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fresenius Medical Care AG & Co. KGaA dividends
- Dividend yield
- 3.89%
- Forward dividend
- 1.73 USD
- Payout ratio
- 43.2%
- Ex-dividend date
- May 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 422M | 1.45 | 43.2% |
| 2024 | EUR 349M | 1.19 | 64.9% |
| 2023 | USD 329M | 1.12 | 65.9% |
| 2022 | USD 396M | 1.35 | 58.7% |
| 2021 | USD 392M | 1.34 | 40.5% |
| 2020 | USD 351M | 1.19 | 30.2% |
| 2019 | USD 355M | 1.17 | 29.6% |
| 2018 | USD 325M | 1.06 | 16.4% |
| 2017 | USD 294M | 0.96 | 23.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 3:1 on Sep 6, 2007.
Who owns Fresenius Medical Care AG & Co. KGaA
- Insiders 25.02%
- Institutions 53.63%
- Public & others 21.36%
- Shares outstanding 260M
- Free float 192M
Fresenius Medical Care AG & Co. KGaA company profile
- Company name
- Fresenius Medical Care AG & Co. KGaA
- Ticker
- FMCQF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 106,291
- Fiscal year end
- December
- Address
- Else-Kröner-Strasse 1, Bad Homburg, Germany, 61352
- Phone
- 49 6172 609 0
- Website
- freseniusmedicalcare.com
About Fresenius Medical Care AG & Co. KGaA
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Fresenius Medical Care AG & Co. KGaA management
10- Mr. Shervin J. KorangyCEO & Chairman of the Management Board · born 1974
- Mr. Martin FischerCFO & Member of the Management Board · born 1977
- Dr. Jorg HaringMember of the Management Board, Global Head of Legal,Compliance & Human Resources and Labor Director · born 1970
- Mr. Joseph E. Turk Jr.CEO of Care Enablement & Member of Management Board · born 1968
- Dr. Charles Hugh-Jones M.D.Global Chief Medical Officer & Member of Management Board · born 1970
- Ms. Cassie McLeanCEO of Care Delivery & Member of Management Board · born 1978
- Dr. Dominik HegerExecutive VP and Head of Investor Relations, Strategic Development & Communications
- Mr. Joachim WeithSenior Vice President of Corporate Communications & Governmental Affairs
- Dr. Gail-Suzanne BrownSenior Vice President of Research & Development
- Mr. Glenn SlaterSenior Vice President of Manufacturing and Supply Chain Operations